Jack Allen
Stock Analyst at Baird
(0.84)
# 3,429
Out of 5,182 analysts
39
Total ratings
36.67%
Success rate
-16.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Neutral | $7 → $13 | $14.09 | -7.74% | 3 | Apr 27, 2026 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $7 → $9 | $2.28 | +294.74% | 4 | Apr 14, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $52 → $44 | $54.83 | -19.75% | 3 | Nov 11, 2025 | |
| VOR Vor Biopharma | Upgrades: Outperform | $20 → $64 | $16.94 | +277.80% | 5 | Oct 15, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $7 → $12 | $6.81 | +76.21% | 5 | Oct 2, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $2.39 | +67.36% | 2 | May 14, 2025 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $11.04 | +262.32% | 2 | Nov 15, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $8.16 | +2,105.88% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $0.25 | +3,105.13% | 1 | Jun 13, 2024 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $84 | $29.58 | +183.98% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.37 | +264.96% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.87 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $4.05 | +122.22% | 1 | Oct 7, 2021 |
Intellia Therapeutics
Apr 27, 2026
Maintains: Neutral
Price Target: $7 → $13
Current: $14.09
Upside: -7.74%
Allogene Therapeutics
Apr 14, 2026
Maintains: Outperform
Price Target: $7 → $9
Current: $2.28
Upside: +294.74%
CRISPR Therapeutics AG
Nov 11, 2025
Maintains: Neutral
Price Target: $52 → $44
Current: $54.83
Upside: -19.75%
Vor Biopharma
Oct 15, 2025
Upgrades: Outperform
Price Target: $20 → $64
Current: $16.94
Upside: +277.80%
Taysha Gene Therapies
Oct 2, 2025
Maintains: Outperform
Price Target: $7 → $12
Current: $6.81
Upside: +76.21%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $2.39
Upside: +67.36%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $11.04
Upside: +262.32%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $8.16
Upside: +2,105.88%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $0.25
Upside: +3,105.13%
Immunocore Holdings
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $29.58
Upside: +183.98%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.37
Upside: +264.96%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.87
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $4.05
Upside: +122.22%